Michele Maffezzoli
Parma, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma.
Journal: Tumori
Published: May 04, 2026
Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group.
Journal: Cancer metastasis reviews
Published: April 02, 2026
The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study.
Journal: The oncologist
Published: February 08, 2026
Engineering the Future of ADCs in Non-Small Cell Lung Cancer.
Journal: Oncology research
Published: December 22, 2025
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study.
Journal: Cancer immunology, immunotherapy : CII
Published: October 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort.
Journal: European urology open science
Published: October 16, 2025
When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinoma.
Journal: Critical reviews in oncology/hematology
Published: September 12, 2025
Who Truly Benefits From First-Line Intensification in EGFR-Mutant NSCLC?
Journal: Current oncology reports
Published: August 08, 2025
Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic Review.
Journal: Oncology research
Published: July 18, 2025
The Role of Circulating Tumor DNA in Patients Treated with Adjuvant Immune Checkpoint Inhibitors: Clinical Reality or Distant Horizon?
Journal: Current oncology reports
Published: June 20, 2025
New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?-a narrative review.
Journal: Chinese clinical oncology
Published: March 26, 2025
Last Updated: 09/26/2026